PRECLINICAL DEVELOPMENT

Extensive preclinical data have been generated to demonstrate that CaP is safe and effective for both injection and mucosal administration of human as well as veterinary vaccines. In preclinical studies, the adjuvant activity and antigen delivery with CaP nanoparticles has been demonstrated using many viral or bacterial antigens by parenteral or mucosal administration:


    • Seasonal flu (H3N2, H1N1)
    • H5N1 avian flu strain
    • H1N1 swine flu strain
    • Genital herpes (HSV-2)
    • HIV
    • Epstein Barr
    • Anthrax
    • Malaria
    • Hepatitis B
    • Tetanus
    • Tuberculosis
    • Dengue-specific peptides

 

In most studies, CaP indicated significant dose sparing potential, often leading to the use of lower vaccine dosage (e.g. flu vaccines) while maintaining effectiveness with improved safety profile. Data also indicated CaP nanoparticles' ability to induce both Th1- and Th2-type responses, CTL response, and mucosal IgA when administered by mucosal or injection routes.  



Our studies to establish CaP nanoparticle as the next generation vaccine adjuvant depends largely on partnership with those developing vaccines or antigens. We also continue pre-clinical development of our adjuvant with special focus on influenza vaccines, particularly for nasal administration, and vaccines for therapeutic use.